Lv4
546 积分 2021-10-28 加入
Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study
1天前
已完结
Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer
2天前
已完结
Present situation and prospect of immunotherapy for unresectable locally advanced esophageal cancer during peri-radiotherapy
10天前
已完结
Combine radiotherapy and immunotherapy in esophageal squamous cell carcinoma
10天前
已完结
Perioperative immunotherapy for esophageal squamous cell carcinoma
10天前
已完结
Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy
10天前
已完结
Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trial
10天前
已完结
Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions
10天前
已完结
Case report of radiotherapy combined with anlotinib and immunotherapy for a patient with esophageal cancer and esophageal fistula
10天前
已完结
The treatment efficacy and prognosis of each treatment in early postoperative recurrence of esophageal squamous cell carcinoma
10天前
已完结
Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects
皖公网安备34019202002308
